GlassScriptPhysician profile
John T Pajka
NPI 1861469108
$4,516.38
in general payments reported to CMS, 2019-2025
10 companies · $280 in 2025
The $280 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $13.80 · 2021: $76.21 · 2022: $126 · 2023: $3,819 · 2024: $22.64 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Charitable Contribution: $3,400 · Food and Beverage: $721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Charitable Contribution | $3,400.08 |
| Food and Beverage | $720.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microsurgical Technology, INC. | $3,400.08 | 2023 | |
| Alcon Vision LLC | $176.22 | 2019-2023 | Clareon |
| Johnson & Johnson Surgical Vision, INC. | $163.83 | 2019-2025 | Veritas Vision System, Tecnis Iol |
| Abbvie INC. | $156.31 | 2023-2024 | |
| Bausch & Lomb Americas INC. | $149.46 | 2022-2025 | Stellaris |
| Carl Zeiss Meditec USA, INC. | $148.98 | 2023 | |
| Allergan, INC. | $141.09 | 2019-2021 | |
| Rxsight INC | $120.04 | 2025 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Carl Zeiss Meditec, INC. | $60.37 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$115,959,906.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pajka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.